Category: News from USA
This Cancer Biotech Startup Raises Over 40% Higher in IPO than Proposed Goal
The cancer startup develops novel immunotherapies that target the immune-suppressive tumor microenvironment to attack cancer. The company is developing immuno-oncology drugs which could be combined with existing immunotherapies to enhance the efficiency of detecting and killing cancer cells.
Genprex Raises $6.4 M in IPO, Could Bring “Game-Changing” Immuno-Gene Therapy for Advanced Lung Cancer
Genprex raised $6.4 million in IPO at a share price of $5. Unlike most of the commercial blockbuster lung cancer immunotherapies, its unique lead candidate, Oncoprex® targets advanced lung cancer treatment.
FDA Grants Orphan Drug Status to PET imaging agent CLR 131 for a Rare Cancer
Positron Emission Tomography (PET) imaging makes the cancer detection more sensitive and less toxic to the normal cells. PET imaging ...
AI-Based Software EyeArt™ in Smartphone Could Prevent Vision Loss in 90% Diabetic People
KEY POINTS One in five diabetic Indians is at risk of developing diabetic retinopathy, which can lead to blindness. Eyenuk’s ...
Gilead Company, Kite Collaborates with Sangamo to Develop Engineered Cell Therapies for Cancer
Gene therapy company, Sangamo Therapeutics collaborated with Gilead Sciences subsidiary, Kite Pharma to develop next-generation ex vivo (out of the ...
Astellas Buys Universal Cells in $102.5M Deal to Develop Universal Donor Cells
Japanese pharma company, Astellas acquired the US-based biotech firm, Universal Cells. Astellas will pay up to $102.5 million upfront plus ...
Novartis Ties with Cancer Targeted Technology to Improve Diagnostics for Prostate Cancer
Novartis’ nuclear medicine subsidiary, Advanced Accelerator Applications (AAA) inked a global partnership with US-based Cancer Targeted Technology (CTT) for the ...
Pfizer’s Lorlatinib Gets FDA Priority Review Status to Treat ALK-Positive Lung Cancer
KEY POINTS Lorlatinib is a next-generation ALK/ROS1 tyrosine kinase inhibitor. Last year, lorlatinib had received Breakthrough Therapy designation from the ...
Amicus’ Fabry Disease drug, Migalastat Gets Ready for Approval in the US
Rare diseases company, Amicus Therapeutics’ New Drug Application (NDA) for migalastat (migalastat HCl), for filing under priority review is accepted ...